Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 4/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384058 | 0.92 | ADORA2A (0.40) | EGFRADORA2APTGIRDHODHFBP1 | |
| SCHEMBL4387719 | 0.92 | L3MBTL1 (0.35) | EGFRPTGIRFBP1GSK3B | |
| SCHEMBL4387626 | 0.88 | PTGIR (0.33) | EGFRPTGIRDHODH | |
| SCHEMBL4383980 | 0.88 | PTGIR (0.39) | EGFRPTGIRGSK3B | |
| SCHEMBL4378282 | 0.87 | PTGIR (0.35) | EGFRPTGIRGSK3BPTGER4 | |
| SCHEMBL4384051 | 0.86 | GCGR (0.35) | EGFR | |
| SCHEMBL4389505 | 0.85 | PTGIR (0.36) | EGFRPTGIRGSK3BPTGER4 | |
| SCHEMBL4381492 | 0.83 | PTGIR (0.36) | EGFRPTGIRFBP1PTGER4 | |
| SCHEMBL4379839 | 0.79 | ADORA2A (0.35) | ADORA2APTGIRFBP1FABP4FABP5 | |
| SCHEMBL4386746 | 0.79 | EGFR (0.35) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | EGFR 624/4885ADORA2A 3962/4885PTGIR 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.